Details

Autor(en) / Beteiligte

• Hatanaka, Takeshi
• Kakizaki, Satoru
• Hiraoka, Atsushi
• Tada, Toshifumi
• Hirooka, Masashi
• Kariyama, Kazuya
• Tani, Joji
• Atsukawa, Masanori
• Takaguchi, Koichi
• Itobayashi, Ei
• Fukunishi, Shinya
• Tsuji, Kunihiko
• Ishikawa, Toru
• Tajiri, Kazuto
• Ochi, Hironori
• Yasuda, Satoshi
• Toyoda, Hidenori
• Ogawa, Chikara
• Nishimura, Takashi
• Shimada, Noritomo
• Kawata, Kazuhito
• Kosaka, Hisashi
• Tanaka, Takaaki
• Ohama, Hideko
• Nouso, Kazuhiro
• Morishita, Asahiro
• Tsutsui, Akemi
• Nagano, Takuya
• Itokawa, Norio
• Okubo, Tomomi
• Arai, Taeang
• Imai, Michitaka
• Naganuma, Atsushi
• Koizumi, Yohei
• Nakamura, Shinichiro
• Joko, Kouji
• Kaibori, Masaki
• Iijima, Hiroko
• Hiasa, Yoichi
• Kumada, Takashi

Titel

Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

Ist Teil von

• Hepatology international, 2022-10, Vol.16 (5), p.1150-1160

Ort / Verlag

New Delhi: Springer India

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Aim This study aimed to investigate the utility of C-reactive protein (CRP) and alpha-fetoprotein (AFP) in immunotherapy (CRAFITY) score in hepatocellular carcinoma (HCC) patients receiving atezolizumab and bevacizumab (Atez/Bev). Methods This retrospective cohort study included a total of 297 patients receiving Atez/Bev from September 2020 to November 2021 at 21 different institutions and hospital groups in Japan. Patients with AFP ≥ 100 ng/mL and those with CRP ≥ 1 mg/dL were assigned a CRAFITY score of 1 point. Results The patients were assigned CRAFITY scores of 0 points ( n  = 147 [49.5%]), 1 point ( n  = 111 [37.4%]), and 2 points ( n  = 39 [13.1%]). AFP ≥ 100 ng/mL and CRP ≥ 1.0 mg/dL were significantly associated with progression-free survival (PFS) and overall survival (OS). The median PFS in the CRAFITY score 0, 1, and 2 groups was 11.8 months (95% confidence interval [CI] 6.4-not applicable [NA]), 6.5 months (95% CI 4.6–8.0), and 3.2 months (95% CI 1.9–5.0), respectively ( p  < 0.001). The median OS in patients with CRAFITY score 0, 1 and 2 was not reached, 14.3 months (95% CI 10.5-NA), and 11.6 months (95% CI 4.9-NA), respectively. The percentage of patients with grade ≥ 3 liver injury, any grade of decreased appetite, any grade of proteinuria, any grade of fever, and any grade of fatigue was lowest in patients with a CRAFITY score of 0, followed by patients with CRAFITY scores of 1 and 2. Conclusions The CRAFITY score is simple and could be useful for predicting therapeutic outcomes and treatment-related adverse events.